The combination of Sirolimus antiproliferative action combined with biodegradable polymer and a proven balloon catheter sets new standards in treatment of clinically complex lesions.

Carrier coating and drug are absorbed simultaneously within three months, which covers exactly the time where restenosis tend to occur most frequently.

Sirolimus is associated with minimal neointimia hyperplasia & Sirolimus eluting stents produce a significant lower incidence of major adverse cardiac events (MACE).